Countermovement jump height

Method

Vertical displacement of the centre of mass in a countermovement jump, by force platform, contact mat, or optical system. The apparatus is recorded on the edge — jump-mat and force-plate estimates differ systematically.

The method is part of the endpoint identity. Studies measuring the same quantity by a different method are held as separate endpoints.

Notes

The most frequently measured endpoint in the survey, in four of fourteen abstracts, and previously unmappable. CMJ added 2026-08-23 after a two-pass-agreed caffeine claim was refused on the span "CMJ performance", which shares no scored word with this entry. The abbreviation is near-universal in this literature and collides with no other outcome's vocabulary. Note the claim was refused for a SECOND and correct reason — "showed a positive effect on" states no direction of movement — and remains refused; only the object half was the defect. NOT peak-power-output. That node is mechanical power in watts from a cycle ergometer effort; this is a displacement in centimetres from a whole-body ballistic movement. They correlate and they are not the same measurement, and an edge pooling them would claim a wattage no trial reported.

Findings

2 findings from 2 compounds, strongest first.

• creatine — increases

  AWell establishedGrade A, Well established. Replicated human trial evidence, consistent direction.Finding

  “CMJ height also increased significantly in the creatine group (p = 0.005).”

  Study

  RCT

  Participants

  23

  Duration

  3 months

  Dose

  3 g/day creatine monohydrate, five days per week

  Population

  amateur male soccer players aged 18-35; secondary outcome

  Effectiveness of a soccer injury prevention program based on creatine supplementation and internal load monitoring: a randomized controlled pilot study.2026PMID:41704196

• caffeine — no detected effect on

  BLikelyGrade B, Likely. Human evidence, limited replication or design limits.FindingNull result

  “CMJ performance was not improved by caffeine supplementation (WMD = 1.17, 95%CI: –0.02 to 2.36, p = 0.05).”

  Study

  meta-analysis

  Dose

  Acute single dose, 2-6 mg/kg, ingested before the performance test

  Population

  Healthy young adults (active and sedentary), pooled across CYP1A2 genotypes; countermovement jump height in cm per the review Methods; secondary endpoint (the review primary outcome was CYP1A2 genotype)

  Effect 1.17 mean difference, 95% CI -0.02 to 2.36

  Does ergogenic effect of caffeine supplementation depend on CYP1A2 genotypes? A systematic review with meta-analysis.2024PMID:38158179